Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review
Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesions were diagnosed as triple-negative subtype and...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1328844/full |
| _version_ | 1797238445579436032 |
|---|---|
| author | Yuxin Ma Xinhong Shi Kun Zhao Shuyi Hu Yue Shi Yingying Jiang Yiling Liu Lin Lu Yuting Chang Fei Zhou Yingying Dai Zipeng Wu Shiyi Li Zhiying Qian Xia Xu Chenchen Li Bo Shen Bo Shen Guoren Zhou Cheng Chen Xiaohua Wang Xiaohua Wang Jifeng Feng Jifeng Feng |
| author_facet | Yuxin Ma Xinhong Shi Kun Zhao Shuyi Hu Yue Shi Yingying Jiang Yiling Liu Lin Lu Yuting Chang Fei Zhou Yingying Dai Zipeng Wu Shiyi Li Zhiying Qian Xia Xu Chenchen Li Bo Shen Bo Shen Guoren Zhou Cheng Chen Xiaohua Wang Xiaohua Wang Jifeng Feng Jifeng Feng |
| author_sort | Yuxin Ma |
| collection | DOAJ |
| description | Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesions were diagnosed as triple-negative subtype and who received tislelizumab plus eribulin treatment and achieved excellent efficacy. To our knowledge, this study is the first attempt to present tislelizumab in combination with eribulin for mTNBC treatment. New treatments resulting in prolonged survival and durable clinical responses would benefit mTNBC patients. Then, we summarize the possible influencing factors of the interaction between tislelizumab and eribulin. |
| first_indexed | 2024-04-24T17:35:45Z |
| format | Article |
| id | doaj.art-1d41af09d69841bdb41b261312b9ab6e |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T17:35:45Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-1d41af09d69841bdb41b261312b9ab6e2024-03-28T05:04:06ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-03-011410.3389/fonc.2024.13288441328844Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature reviewYuxin Ma0Xinhong Shi1Kun Zhao2Shuyi Hu3Yue Shi4Yingying Jiang5Yiling Liu6Lin Lu7Yuting Chang8Fei Zhou9Yingying Dai10Zipeng Wu11Shiyi Li12Zhiying Qian13Xia Xu14Chenchen Li15Bo Shen16Bo Shen17Guoren Zhou18Cheng Chen19Xiaohua Wang20Xiaohua Wang21Jifeng Feng22Jifeng Feng23Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaHuaian Hospital of Huaian City, Huaian Cancer Hospital, Huaian, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Oncology, Province Geriatric Hospital, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaHuaian Hospital of Huaian City, Huaian Cancer Hospital, Huaian, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaHuaian Hospital of Huaian City, Huaian Cancer Hospital, Huaian, Jiangsu, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, ChinaHuaian Hospital of Huaian City, Huaian Cancer Hospital, Huaian, Jiangsu, ChinaMetastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesions were diagnosed as triple-negative subtype and who received tislelizumab plus eribulin treatment and achieved excellent efficacy. To our knowledge, this study is the first attempt to present tislelizumab in combination with eribulin for mTNBC treatment. New treatments resulting in prolonged survival and durable clinical responses would benefit mTNBC patients. Then, we summarize the possible influencing factors of the interaction between tislelizumab and eribulin.https://www.frontiersin.org/articles/10.3389/fonc.2024.1328844/fullmetastatic triple negative breast cancer (mTNBC)immune checkpoint inhibitors (ICIS)tislelizumaberibulin mesylatecase report |
| spellingShingle | Yuxin Ma Xinhong Shi Kun Zhao Shuyi Hu Yue Shi Yingying Jiang Yiling Liu Lin Lu Yuting Chang Fei Zhou Yingying Dai Zipeng Wu Shiyi Li Zhiying Qian Xia Xu Chenchen Li Bo Shen Bo Shen Guoren Zhou Cheng Chen Xiaohua Wang Xiaohua Wang Jifeng Feng Jifeng Feng Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review Frontiers in Oncology metastatic triple negative breast cancer (mTNBC) immune checkpoint inhibitors (ICIS) tislelizumab eribulin mesylate case report |
| title | Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review |
| title_full | Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review |
| title_fullStr | Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review |
| title_full_unstemmed | Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review |
| title_short | Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review |
| title_sort | optimal response to tislelizumab plus chemotherapy in metastatic triple negative breast cancer a case report and literature review |
| topic | metastatic triple negative breast cancer (mTNBC) immune checkpoint inhibitors (ICIS) tislelizumab eribulin mesylate case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1328844/full |
| work_keys_str_mv | AT yuxinma optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT xinhongshi optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT kunzhao optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT shuyihu optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT yueshi optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT yingyingjiang optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT yilingliu optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT linlu optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT yutingchang optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT feizhou optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT yingyingdai optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT zipengwu optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT shiyili optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT zhiyingqian optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT xiaxu optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT chenchenli optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT boshen optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT boshen optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT guorenzhou optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT chengchen optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT xiaohuawang optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT xiaohuawang optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT jifengfeng optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview AT jifengfeng optimalresponsetotislelizumabpluschemotherapyinmetastatictriplenegativebreastcanceracasereportandliteraturereview |